Minoxidil

Minoxidil has separate evidence lanes: FDA-reviewed topical products for pattern hair loss and an oral tablet labeled for severe hypertension. Oral hair use is off-label.

tier S · skin · 45% more reported regrowth with topical 5% versus 2% at week 48

verdict

Labeled topical minoxidil increases hair counts and regrowth in specified pattern-hair-loss populations while treatment continues. A 24-week male trial did not show oral minoxidil superiority on the primary hair-density comparisons, and oral hair use remains off-label.

the core tension

Minoxidil has strong topical hair evidence and strong oral antihypertensive pharmacology. Collapsing those lanes makes topical users inherit oral PK or makes off-label oral hair use look approved and cardiovascularly routine.

what it is

Minoxidil is a small-molecule arteriolar vasodilator. Parent minoxidil, the active sulfate ester metabolite, and a separate 1:1 sulfate salt are distinct identity records.

what it does

Oral minoxidil directly lowers arteriolar resistance in severe hypertension. Sulfation contributes to activity. The exact follicular mechanism remains incomplete, so vasodilation alone should not be presented as the full explanation of hair growth.

origin

Men's and women's 5% foams have separate topical hair labels, populations, scalp regions, and directions. Oral Loniten is a severe-hypertension product, not an FDA-approved hair-loss tablet.

does it work

A 393-man topical trial found both active strengths better than vehicle and 5% earlier and stronger than 2%. In a separate 90-man double-dummy trial, oral minoxidil did not beat topical 5% on the primary hair-density comparisons; only 68 completed primary follow-up.

key facts

• molecular formula: C9H15N5O (parent minoxidil)
• molecular weight: 209.2487 g/mol (parent minoxidil)
• amino acids: n/a (small molecule, not a peptide)
• half-life: 4.2 h mean plasma value for the oral severe-hypertension tablet, not topical products
• type: arteriolar vasodilator; follicular activity depends partly on sulfation
• CAS: 38304-91-5
• 393 men in the 48-week topical trial
• 90 men randomized in the oral-versus-topical trial
• 68 completed primary efficacy follow-up in that trial

frequently asked questions

Is minoxidil FDA approved for hair loss?

Topical minoxidil products have FDA-reviewed OTC hair-regrowth labels. Oral minoxidil is not FDA-approved for hair loss; its label is for severe hypertension.

Do all 5% topical products use the same directions?

No. The reviewed men's and women's foam labels differ in population, scalp region, and frequency. Product-specific labeling matters.

Is oral minoxidil better for hair?

The cited 24-week male trial did not show oral superiority on the primary hair-density outcomes. A secondary vertex photograph result cannot replace the primary analysis.

What is the oral half-life?

The oral severe-hypertension label reports a mean plasma half-life of 4.2 hours. That is not topical foam or solution PK, and blood-pressure effects last longer than plasma persistence.

Can tablets be turned into an equivalent topical product?

The oral label says extemporaneous topical preparations made from tablets were not established safe or effective and may expose users to systemic effects.

related peptides

• Finasteride: The minoxidil evidence cited on this page does not establish finasteride's route, mechanism, approval, or outcomes.
• Dutasteride: The minoxidil evidence cited on this page does not establish dutasteride's route, approval, trial record, or outcomes.

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.